Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof
Disclosed are a carrier for delivering a negatively charged drug, comprising a cationic lipid represented by formula 1, and a preparation method thereof. Also disclosed is a pharmaceutical composition comprising a negatively charged drug and a cationic lipid represented by formula 1, wherein the negatively charged drug forms a complex with the cationic lipid. The composition can increase the in vivo stability of the negatively charged drug after local or systemic administration and allows the intracellular delivery of the negatively charged drug. Thus, the composition will be useful for improving the therapeutic effect of the negatively charged drug.
1. A pharmaceutical composition comprising a negatively charged drug and a cationic lipid selected from a group consisting of 1,6-dioleoyl triethylenetetramide, 1,8-dilinoleoyl tetraethylenepentamide, 1,4-dimyristoleoyl diethylenetriamide, 1,10-distearoyl pentaethylenehexamide, and 1,10-dioleoyl pentaethylenehexamide.
2. The pharmaceutical composition of claim 1 , wherein the composition is in the form of a liposome, a micelle, an emulsion or a nanoparticle.
3. The pharmaceutical composition of claim 1 , wherein the ratio of the charge of the anionic drug to the charge of the cationic lipid is 0.1 to 128.
4. The pharmaceutical composition of claim 1 , wherein the cationic lipid is contained in an amount of 0.001 to 10 wt % based on the total weight of the composition.
5. The pharmaceutical composition of claim 1 , wherein the composition is in the form of a micelle comprising a negatively charged drug, a cationic lipid, and an amphiphilic block copolymer,
wherein the negatively charged drug forms a complex with the cationic lipid, and the complex is entrapped in the micelle structure of the amphiphilic block copolymer.
6. The pharmaceutical composition of claim 1 , wherein the composition is in the form of a liposome comprising a negatively charged drug, a cationic lipid, and a cell-fusogenic phospholipid,
wherein the negatively charged drug forms a complex with the cationic lipid, and the complex is bound to a liposome formed from the cell-fusogenic phospholipid.
7. The pharmaceutical composition of claim 1 , wherein the composition is in the form of a micelle comprising a negatively charged drug, a cationic lipid, and a surfactant,
wherein the negatively charged drug forms a complex with the cationic lipid, and the complex is entrapped in the micelle structure of the surfactant.
8. The pharmaceutical composition of claim 1 , wherein the composition is in the form of an emulsion comprising a negatively charged drug, a cationic lipid selected from a group consisting of 1,6-dioleoyl triethylenetetramide, 1,8-dilinoleoyl tetraethylenepentamide, 1,4-dimyristoleoyl diethylenetriamide, 1,10-distearoyl pentaethylenehexamide, and 1,10-dioleoyl pentaethylenehexamide, and a surfactant,
wherein the negatively charged drug forms a complex with the cationic lipid, and the complex is entrapped in the emulsion.
9. The pharmaceutical composition of claim 1 , wherein the negatively charged drug is an antisense oligonucleotide, an aptamer or a small interfering RNA (siRNA).